Efficacy of Combination Therapy of Clindamycin and Rifampicin in Recurrent Furunculosis
DOI:
https://doi.org/10.66344/jpad.v32i2.1907Abstract
Objective To assess the efficacy of combination therapy of clindamycin and rifampicin in recurrent furunculosis.
Methods This study was conducted at the outpatient Department of Dermatology (Khalifa Gul Nawaz teaching hospital MTI, Bannu, Bannu Medical College) from December 2019 to December 2020. A total of 150 patients aged between 18 and 65 years of recurrent furunculosis were enrolled. Mupirocin 2 percent was applied on the lesions involving the nostrils, and anal region twice daily, and took oral 400mg tablet of metronidazole three times daily for 10 days. They were prescribed Clindamycin 300 mg twice daily and Rifampicin 600 mg OD for 10 days. The drug was considered efficacious if the patient had no episode of furuncles during a 2-3 month follow‐up period.
Results There were 74 patients in Group A and 76 in Group B. Patients in Groups A and B had 30 (40.54%) and 46 (60.52%) male patients and 44 (59.45%) and 30 (39.47%) female patients, respectively. Patients had five major sites of disease recurrence; face 31 (20.6%), neck 30 (20%), axilla 32 (21.3%), buttock 36 (24%) and groin in 21 (14%) patients.
Conclusion Combination therapy of clindamycin, rifampicin, metronidazole and mupirocin can be considered a promising therapy for treating recurrent furunculosis.
References
1. El-Gilany AH, Fathy H. Risk factors of recurrent furunculosis. Dermatol Online J. 2009;15:16.
2. Dahl MV. Strategies for the management of recurrent furunculosis. South Med J. 1987;80:352-6.
3. Demos M, McLeod MP, Nouri K. Recurrent furunculosis: a review of the literature. Br J Dermatol. 2012;167(4):725-32.
4. Aminzadeh A, Demircay Z, Ocak K, Soyletir G. Prevention of chronic furunculosis with low‐dose azithromycin. J Dermatolog Treat. 2007;18(2):105-8.
5. Bukki J, Klein J, But L, et al. Methicillin-resistant Staphylococcus aureus (MRSA) management in palliative care units and hospices in Germany: a nationwide survey on patient isolation policies and quality of life. Palliat Med. 2013;27:84-90.
6. Dissemond J. Methicillin resistant Staphylococcus aureus (MRSA): diag-nostic, clinical relevance andtherapy. J Dtsch Dermatol Ges. 2009;7:544-51; quiz 552-3.
7. Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz, Qualtiy of Life Group of the French Society of Dermatology Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2007;56:621-3.
8. Onderdijk AJ, van der Zee HH, Esmann S, et al. Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2013;27:473-8.
9. Nowicka D, Grywalska E. Staphylococcus aureus and Host Immunity in Recurrent Furunculosis. Dermatology. 2019;235(4):295-305.
10. Adam Schaffer, Jean C. Lee. Staphylococcal vaccines and immunotherapies. Infect Dis Clin North Am. 2009;23(1):153-71.
11. Ibler KS, Kromann CB. Recurrent Furunculosis-Challenges and Management: A Review. Clin Cosmet Investig Dermatol. 2014;7:59-64.
12. Shallcross LJ, Hayward AC, Johnson AM, Petersen I. Incidence and recurrence of boils and abscesses within the first year: a cohort study in UK primary care. Br J Gen Pract. 2015;65(639):e668-76.
13. Hamaliaka A, Novikova I. Nitric oxide production disorders in leukocytes of patients with recurrent furunculosis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010;154(2):163-7.
14. Ebright JR, Pieper B. Skin and soft tissue infections ininjection drug users. Infect Dis Clin North Am. 2002;16:697-712.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Qazi Syed Irfanullah Shah, Naimat Ullah, Shaista Rasheed, Taimoor Nawab Khan, Paride Abliz, Xue feng wan
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
